Storia in 7 fonti

Roche to Pay Nurix as Much as $2.3 Billion in Cancer Deal

(Bloomberg) -- Roche Holding AG agreed to pay Nurix Therapeutics Inc. as much as $2.3 billion for rights to an experimental blood-cancer drug, betting it can help patients whose disease stops responding to existing treatments.

Raccontata da

Confronto fonti

6 prospettive sulla stessa storia

AI · summaries

swissinfo.chStai leggendo1 mese fa

Roche to Pay Nurix as Much as $2.3 Billion in Cancer Deal

originale

Timeline cronologica

lunedì 8 giugno 2026·biopharmadive.com
Roche stakes $700M on Nurix’s protein-degrading drug
Potentially worth up to $2.3 billion, the collaboration is a bet that drugs able to eliminate the “BTK” enzyme will prove superior to existing medicines that block its activity.
lunedì 8 giugno 2026·36kr.com
隆基绿能：控股股东李振国解除质押1.55亿股-36氪
36氪获悉，隆基绿能公告，控股股东李振国将其原质押给国通信托的1.55亿股无限售流通股办理了解除质押手续，占其所持股份的14.52%。本次解除质押后，李振国累计质押公司股份2.1亿股，占其持股数量的19.68%。

Roche to Pay Nurix as Much as $2.3 Billion in Cancer Deal

Confronto fonti

Roche to Pay Nurix as Much as $2.3 Billion in Cancer Deal

Timeline cronologica

Roche stakes $700M on Nurix’s protein-degrading drug

隆基绿能：控股股东李振国解除质押1.55亿股-36氪

Roche stakes $700M on Nurix’s protein-degrading drug

Nurix to work with Roche on BTK degrader in pact worth up to $2.3B

Nurix Therapeutics Gains Ground As Roche Partnership Targets Growing B-Cell Blood Cancer Market - Nurix T

Roche Inks $2.3 Billion Deal, Sending Biotech Stock Flying

Roche fecha acordo de US$ 2,3 bilhões para remédio contra câncer

Roche joins Californian Nurix oncology programme

Roche to Pay Nurix as Much as $2.3 Billion in Cancer Deal

Nurix to work with Roche on BTK degrader in pact worth up to $2.3B

Roche fecha acordo de US$ 2,3 bilhões para remédio contra câncer

Nurix Therapeutics Gains Ground As Roche Partnership Targets Growing B-Cell Blood Cancer Market - Nurix T

Roche Inks $2.3 Billion Deal, Sending Biotech Stock Flying